Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brensocatib PK in Hepatic Impairment
NCT05517525Phase 1Completed
- Sponsor
- Insmed Incorporated
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brensocatib in Non-cystic fibrosis bronchiectasis (NCFB) (4 arms), sponsored by Insmed Incorporated. Primary endpoint: Area Under the Concentration Time Curve at Day 9. Started Oct 2022; status: completed.
02
Drugs
brensocatib
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT05517525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517525.